Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons


Bagsværd, Denmark, 12 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonDavid Moore
2 Reason for the notification
a)Position/statusExecutive Vice President, head of Corporate Development
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

 
 Identification codeNovo Nordisk B DK0062498333
b)Nature of the transactionOther transaction (acquisition of shares in accordance with the recruitment package)
c)Price(s) and volume(s)    
 Price(s)Volume(s) 
 DKK 0.0018,634 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price



18,634 shares
DKK 0.00
e)Date of the transaction2024-11-11
f)Place of the transactionOutside a trading venue


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonDavid Moore
2 Reason for the notification
a)Position/statusExecutive Vice President, head of Corporate Development
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

 
 Identification codeNovo Nordisk B DK0062498333
b)Nature of the transactionSale of Shares
c)Price(s) and volume(s)    
 Price(s)Volume(s) 
 DKK 759.969,919 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price



9,919 shares
DKK 7,538,047.37
e)Date of the transaction2024-11-11
f)Place of the transactionNasdaq Copenhagen


Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.


Contacts for further information

Media: 
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

 
Liz Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com

 
Investors: 
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

 
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

 
Sina Meyer
+45 3079 6656
azey@novonordisk.com

 
Ida Schaap Melvold
+45 3077 5649
idmg@novonordisk.com

 
Frederik Taylor Pitter
+1 609 613 0568
fptr@novonordisk.com
 

Company announcement No 87 / 2024

Attachment



Attachments

CA241112-insider-trading